836 related articles for article (PubMed ID: 37229456)
41. Altered Gut Microbiota in Type 2 Diabetes: Just a Coincidence?
Sircana A; Framarin L; Leone N; Berrutti M; Castellino F; Parente R; De Michieli F; Paschetta E; Musso G
Curr Diab Rep; 2018 Sep; 18(10):98. PubMed ID: 30215149
[TBL] [Abstract][Full Text] [Related]
42. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
43. Different Strategies Targeting Gut Microbiota for the Management of Several Disorders: A Sustainable Approach.
Chowdhury M; Raj Chaudhary N; Kaur P; Goyal A; Sahu SK
Infect Disord Drug Targets; 2024; 24(5):e160124225675. PubMed ID: 38317473
[TBL] [Abstract][Full Text] [Related]
44. Interactions between Gut Microbiota and Oral Antihyperglycemic Drugs: A Systematic Review.
Mindrescu NM; Guja C; Jinga V; Ispas S; Curici A; Nelson Twakor A; Pantea Stoian AM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542513
[TBL] [Abstract][Full Text] [Related]
45. Targeting the Gut Microbiota for Remediating Obesity and Related Metabolic Disorders.
Wang B; Wang L; Wang H; Dai H; Lu X; Lee YK; Gu Z; Zhao J; Zhang H; Chen W; Wang G
J Nutr; 2021 Jul; 151(7):1703-1716. PubMed ID: 33982127
[TBL] [Abstract][Full Text] [Related]
46. Characteristics of the Gut Microbiota and Potential Effects of Probiotic Supplements in Individuals with Type 2 Diabetes
Ballan R; Saad SMI
Foods; 2021 Oct; 10(11):. PubMed ID: 34828808
[TBL] [Abstract][Full Text] [Related]
47. The Human Gut Microbiome as a Potential Factor in Autism Spectrum Disorder.
Alharthi A; Alhazmi S; Alburae N; Bahieldin A
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163286
[TBL] [Abstract][Full Text] [Related]
48. Interactions Between Gut Microbiota, Host, and Herbal Medicines: A Review of New Insights Into the Pathogenesis and Treatment of Type 2 Diabetes.
Zheng Y; Gou X; Zhang L; Gao H; Wei Y; Yu X; Pang B; Tian J; Tong X; Li M
Front Cell Infect Microbiol; 2020; 10():360. PubMed ID: 32766169
[TBL] [Abstract][Full Text] [Related]
49. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Obesity and Obesity-Associated Metabolic Disorders: Current Evidence and Perspectives.
Vallianou N; Stratigou T; Christodoulatos GS; Dalamaga M
Curr Obes Rep; 2019 Sep; 8(3):317-332. PubMed ID: 31175629
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic interventions for gut dysbiosis and related disorders in the elderly: antibiotics, probiotics or faecal microbiota transplantation?
Vemuri RC; Gundamaraju R; Shinde T; Eri R
Benef Microbes; 2017 Apr; 8(2):179-192. PubMed ID: 28008784
[TBL] [Abstract][Full Text] [Related]
51. Gut Microbiota and Metabolic Disorders: Advances in Therapeutic Interventions.
Akash MSH; Fiayyaz F; Rehman K; Sabir S; Rasool MH
Crit Rev Immunol; 2019; 39(4):223-237. PubMed ID: 32421966
[TBL] [Abstract][Full Text] [Related]
52. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus.
Kootte RS; Vrieze A; Holleman F; Dallinga-Thie GM; Zoetendal EG; de Vos WM; Groen AK; Hoekstra JB; Stroes ES; Nieuwdorp M
Diabetes Obes Metab; 2012 Feb; 14(2):112-20. PubMed ID: 21812894
[TBL] [Abstract][Full Text] [Related]
53. Microbiota medicine: towards clinical revolution.
Gebrayel P; Nicco C; Al Khodor S; Bilinski J; Caselli E; Comelli EM; Egert M; Giaroni C; Karpinski TM; Loniewski I; Mulak A; Reygner J; Samczuk P; Serino M; Sikora M; Terranegra A; Ufnal M; Villeger R; Pichon C; Konturek P; Edeas M
J Transl Med; 2022 Mar; 20(1):111. PubMed ID: 35255932
[TBL] [Abstract][Full Text] [Related]
54. Relationship between gut microbiota, probiotics, and type 2 diabetes mellitus.
Salgaço MK; Oliveira LGS; Costa GN; Bianchi F; Sivieri K
Appl Microbiol Biotechnol; 2019 Dec; 103(23-24):9229-9238. PubMed ID: 31664483
[TBL] [Abstract][Full Text] [Related]
55. Microbiota dysbiosis and myasthenia gravis: Do all roads lead to Rome?
Kapoor B; Gulati M; Gupta R; Singla RK
Autoimmun Rev; 2023 May; 22(5):103313. PubMed ID: 36918089
[TBL] [Abstract][Full Text] [Related]
56. Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites.
Chen S; Jiao Y; Han Y; Zhang J; Deng Y; Yu Z; Wang J; He S; Cai W; Xu J
Acta Diabetol; 2024 Apr; 61(4):393-411. PubMed ID: 38227209
[TBL] [Abstract][Full Text] [Related]
57. Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis.
Kujawa D; Laczmanski L; Budrewicz S; Pokryszko-Dragan A; Podbielska M
Gut Microbes; 2023 Dec; 15(2):2274126. PubMed ID: 37979154
[TBL] [Abstract][Full Text] [Related]
58. Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease.
Lim EY; Song EJ; Shin HS
J Microbiol Biotechnol; 2023 Sep; 33(9):1111-1118. PubMed ID: 37164760
[TBL] [Abstract][Full Text] [Related]
59. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
Suk KT; Kim DJ
Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
[TBL] [Abstract][Full Text] [Related]
60. Gut microbiota and acute graft-versus-host disease.
Yoshioka K; Kakihana K; Doki N; Ohashi K
Pharmacol Res; 2017 Aug; 122():90-95. PubMed ID: 28576475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
